<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETIDOCAINE HYDROCHLORIDE</span><br/>(e-ti'doe-kane)<br/><span class="topboxtradename">Duranest<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">local anesthetic (amide-type)</span><br/><b>Prototype: </b>Procaine HCl<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% injection</p>
<h1><a name="action">Actions</a></h1>
<p>Amide-type local anesthetic similar to bupivacaine in action and uses.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits sodium fluxes into nerve cell required for initial depolarization, propagation, and conduction of nerve impulse.</p>
<h1><a name="uses">Uses</a></h1>
<p>Infiltration anesthesia, peripheral nerve blocks (intercostal, ulnar, inferior alveolar, brachial plexus) and central neural
         block (lumbar or caudal epidural blocks).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known sensitivity to amide-type anesthetics, parabens, bisulfites; acidosis, heart block, severe hemorrhage, severe hypotension,
         hypertension; cerebrospinal deformities or disease; spinal block, epidural anesthesia in vaginal delivery; injection into
         inflamed or infected area. Safety during pregnancy (category B) (except during labor), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Known drug sensitivities; impaired cardiac function; kidney or liver disease; severe shock; older adult, debilitated or severely
         ill patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Percutaneous Infiltration</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.5% solution (max: 300 mg, 400 mg if given with epinephrine)<br/><br/><span class="indicationtitle">Peripheral Nerve Block, Caudal</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.5% or 1% solution (max: 300 mg, 400 mg if given with epinephrine)<br/><br/><span class="indicationtitle">Central Neural Block</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.5% or 1.5% solution (max: 300 mg, 400 mg if given with epinephrine)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Aspirate prior to injection to avoid intravascular injection.</li>
<li>Discard partially used vial of etidocaine, since it has no preservative.</li>
<li>Store at 15°30° C (59°86° F); protect from freezing; protect solutions with epinephrine from
            direct light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-life">Anaphylaxis, anaphylactoid reactions</span>. <span class="typehead">CNS:</span> Nervousness, headache, anxiety, excitement, <span class="speceff-life">convulsions followed by drowsiness, unconsciousness, respiratory arrest</span>. <span class="typehead">CV:</span> Myocardial depression, arrhythmias, <span class="speceff-life">fetal cardiac arrest, bradycardia during delivery</span>, maternal hypotension. <span class="typehead">Special Senses:</span> Blurred vision, tinnitus, pupillary constriction. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Skin:</span> Skin rash, injection site inflammation and pain. <span class="typehead"> Other:</span> Edema, backache. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <span class="classification">maoi</span>, <span class="classification">antihypertensives</span> may increase risk of hypotension. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from parenteral injection sites. <span class="typehead"> Onset:</span>  28 min. <span class="typehead">Duration:</span> 4.513 h. <span class="typehead">Distribution:</span> Crosses blood-brain barrier and placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li> 							Note: When used for peridural analgesia, drug produces a profound degree of motor blockade and abdominal relaxation. 						</li>
<li>Monitor patient's CV and respiratory status continuously during administration.</li>
<li>Administer oxygen at first sign of CNS toxicity. Early warning S&amp;S: Restlessness, anxiety, tinnitus, dizziness, blurred vision,
            tremors, and drowsiness.
         </li>
<li> 							Note: Etidocaine may trigger familial malignant hyperthermia. Early unexplained signs of tachycardia, tachypnea, labile BP, metabolic
            acidosis, and skeletal muscle rigidity may precede temperature elevation. 						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not to chew solid foods or test the anesthetized region by biting or probing before anesthesia wears off to prevent traumatizing
            tongue, lip, and buccal mucosa.
         </li>
<li> 							Note: Patient may experience temporary loss of sensation and motor activity, usually in the lower part of the body, after proper
            administration of epidural anesthesia. 						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>